Wiener Medizinische Wochenschrift

, Volume 168, Issue 5–6, pp 121–132 | Cite as

Orale Antikoagulation mit Vitamin K-Antagonisten – ein Update

  • Christoph Sucker
  • Jens Litmathe


Vitamin K-Antagonisten (VKA) werden zur Prophylaxe und Therapie thrombotischer bzw. thromboembolischer Ereignisse eingesetzt; die wichtigsten Indikationen sind die Antikoagulation bei tiefer Venenthrombose und Lungenembolie, die Antikoagulation bei Patienten mit Vorhofflimmern sowie die Antikoagulation bei Patienten mit mechanischem Herzklappenersatz und somit gelebter Alltag vor dem Hintergrund potentieller kardio-neurologischer Ereignisse. Mit der vorliegenden Arbeit soll ein Überblick über die Antikoagulation mit VKA gegeben werden; hierbei wird auf Wirkungsmechanismen, Indikationen und Effektivität, Durchführung der Antikoagulation, Nebenwirkungen und Monitoring der Behandlung eingegangen.


Vit. K Antagonisten Übersicht Selbst-Management Indikationen Alternativen 

Oral anticoagulation using coumarins – an update


Vitamin K antagonists (VKA) are used for the prophylaxis and treatment of thrombotic and thromboembolic events. Most important indications are venous thrombosis and pulmonary embolism, atrial fibrillation, and mechanical heart-valve replacement. Hence they are from high relevance for the neurologist and his daily praxis in cardio-neurological routine. Here, we give an overview about VKA with focus on mode of action, indications and efficacy, practical aspects of treatment, side effects, and monitoring.


Coumarins Review Self-management Indications Alternatives 



C. Sucker und J. Litmathe geben an, dass kein Interessenkonflikt besteht.


  1. 1.
    Amin A, Marrs JC. Direct oral anticoagulants for the management of Thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost. 2016;22:605–16.CrossRefPubMedGoogle Scholar
  2. 2.
    Ansell J. Point-of-care patient self-monitoring of oral vitamin K antagonist therapy. J Thromb Thrombolysis. 2013;35:339–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Ansell J, Jacobson A, Levy J, International Self-Monitoring Association for Oral Anticoagulation, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol. 2005;9:37–45.CrossRefGoogle Scholar
  4. 4.
    Barcellona D, Fenu L, Cornacchini S, Marongiu F. Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. J Telemed Telecare. 2013;19:298–301.CrossRefPubMedGoogle Scholar
  5. 5.
    Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Benmira S, Banda ZK, Bhattacharya V. Old versus new anticoagulants: focus on pharmacology. Recent Pat Cardiovasc Drug Discov. 2010;5:120–37.CrossRefPubMedGoogle Scholar
  7. 7.
    Bernardo A, Völler H. Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation. Guidelines for „coagulation self-management“. Dtsch Med Wochenschr. 2001;126:346–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Berthold HK. New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients. Z Gerontol Geriatr. 2012;45:498–504.CrossRefPubMedGoogle Scholar
  9. 9.
    Berthold HK. New oral anticoagulants: who really needs them? Internist. 2014;55:93–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Booth SL, Mayer J. Warfarin use and fracture risk. Nutr Rev. 2000;58:20–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Booth SL, Charnley JM, Sadowski JA, Saltzman E, Bovill EG, Cushman M. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Thromb Haemost. 1997;77:504–9.PubMedGoogle Scholar
  12. 12.
    Braun S, Völler H, Soppa C, Taborski U. Update of guidelines for patient self-management of oral anticoagulation. Dtsch Med Wochenschr. 2009;134:695–700.CrossRefPubMedGoogle Scholar
  13. 13.
    Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979–87.CrossRefPubMedGoogle Scholar
  14. 14.
    Butt HR, Allen EU, Bollman JL. A preparation from spoiled sweet clover C3, 3 methylene-bis- (4 hydroxy-coumarin) which prolongs coagulation and prothrombin time of 120 blood: preliminary report of experiments and clinical studies. Proceedings of the statt meetings. Mayo Clin. 1941;16:388–95.Google Scholar
  15. 15.
    Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem. 1941;138:21–33.Google Scholar
  16. 16.
    Daly AK. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013;87:407–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators, et al. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21:279–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Eikelboom JW, Connolly SJ, Brueckmann M, RE-ALIGN Investigators, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994;10:381–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004;10(Suppl.3):58–65.Google Scholar
  21. 21.
    van Gorp RH, Schurgers LJ. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients. 2015;7:9538–57.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hana A, Berthold C, Gunness VR, Hana A, Dooms G, Standhardt H, Koy J, Matgé G, Boecher-Schwarz H, Hertel F. NOAC and intracerebral bleeding – presentation of four cases and review of the literature. Bull Soc Sci Med Grand Duche Luxemb. 2014;1:57–66.Google Scholar
  23. 23.
    Hanslik T, Prinseau J. The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs. 2004;4:43–55.CrossRefPubMedGoogle Scholar
  24. 24.
    Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996;30:416–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Horstkotte D, Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis. 2004;13:335–8.PubMedGoogle Scholar
  26. 26.
    Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65:1239–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1998;128:829–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454–545.CrossRefGoogle Scholar
  29. 29.
    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):419–94.CrossRefGoogle Scholar
  30. 30.
    Krabbe B, Bauersachs RM. Bridging in patients with long-term oral anticoagulation – new recommendations. Dtsch Med Wochenschr. 2016;141:157–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Last JA. The missing link: the story of Karl Paul Link. Toxicol Sci. 2002;66:4–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, Kirchhof P. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111:833–41.CrossRefPubMedGoogle Scholar
  33. 33.
    Linkins LA. Bleeding risks associated with vitamin K antagonists. Blood Rev. 2013;27:111–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Mair H, Sachweh J, Sodian R, et al. Long-term self-management of anticoagulation therapy after mechanical heart valve replacement in outside trial conditions. Interact Cardiovasc Thorac Surg. 2012;14:253–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Mentré F, Pousset F, Comets E, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharm Therap. 1998;63:64–78.CrossRefPubMedGoogle Scholar
  37. 37.
    Neef M, Kerekes Z, Fischer HP, Sauerbruch T, Spengler U. Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases. Digestion. 2003;67:100–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost. 2007;98:570–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Olthof E, de Vries TW. Breast feeding and oral anticoagulants. Tijdschr Kindergeneeskd. 1993;61:175–7.PubMedGoogle Scholar
  40. 40.
    Pilon D, Castilloux AM, Dorais M, LeLorier J. Oral anticoagulants and the risk of osteoporosis fractures among elderly. Pharmacoepidemiol Drug Saf. 2004;13:289–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1‑year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMedGoogle Scholar
  42. 42.
    Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin Reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114:583–6.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Räber L, Piccolo R. CardioPulse: Different bleeding scores and which one should we use ? Eur Heart J. 2016;37:327–31.CrossRefPubMedGoogle Scholar
  44. 44.
    Riley P, Maan A, Korr KS. Direct Oral Anticoagulants (DOAcs): current status among distinct patient subgroups. R I Med J. 2017;100:18–22.Google Scholar
  45. 45.
    Roderick LM. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc. 1929;74:314–5.Google Scholar
  46. 46.
    Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int. 2012;32:1465–76.CrossRefPubMedGoogle Scholar
  47. 47.
    Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care. 2007;10:1–5.PubMedGoogle Scholar
  48. 48.
    Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160:967–73.CrossRefPubMedGoogle Scholar
  49. 49.
    Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA. 1999;281:145–50.CrossRefPubMedGoogle Scholar
  50. 50.
    Schimanski CC, Burg J, Möhler M, et al. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-)acute liver failure. J Hepatol. 2004;41:67–74.CrossRefPubMedGoogle Scholar
  51. 51.
    Siguret V. Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy. Pathol Biol (Paris). 2007;55:295–8.CrossRefGoogle Scholar
  52. 52.
    Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost. 1999;25:103–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227–46.CrossRefPubMedGoogle Scholar
  55. 55.
    Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology. 2008;47:1384–93.CrossRefPubMedGoogle Scholar
  56. 56.
    Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163:931–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Vermeer C, Hamulyák K. Pathophysiology of vitamin K‑deficiency and oral anticoagulants. Thromb Haemost. 1991;66:153–9.PubMedGoogle Scholar
  58. 58.
    Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am. 2000;14:339–53.CrossRefPubMedGoogle Scholar
  59. 59.
    Watzka M, Geisen C, Bevans CG, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost. 2011;9:109–18.CrossRefPubMedGoogle Scholar
  60. 60.
    Wood B, Sholzberg M, Ackery A. Direct oral anticoagulants and the bleeding patient. CMAJ. 2016;188:215.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. 2012;54:207–15.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2017

Authors and Affiliations

  1. 1.Gerinnungszentrum Berlin Dr. SuckerBerlinDeutschland
  2. 2.Klinik für NeurologieRWTH Aachen UniversityAachenDeutschland

Personalised recommendations